Clay Siegall, the co-founder, CEO, President and Chairman of Seattle Genetics, the largest biotech firm in the state of Washington with 900 employees, is at the helm of the development of what could be a line of sought-after drugs for the treatment of various forms of cancer. There are 11 drugs currently being developed and tested by Seattle Genetics, of which 4 are predicted to rake in the highest sales.
The first of these potential blockbuster drugs is Adcetris, a second or third-line treatment for Hodgkin lymphoma approved by the US Food and Drug Administration (FDA). If further tests currently underway manage to reveal Adcetris as having a better effect on patients with Hodgkin lymphoma than current frontline treatments, the sales could be greatly bolstered, with revenues as high as $1 billion predicted by Siegall. The other drugs being researched by Seattle Genetics include 33A, a treatment for Acute Myeloid Leukaemia (AML); 22ME, a drug aimed at curing bladder cancer; and LIV1, a curing aid for breast cancer patients.
Apart from heading pioneering research into cures for various types of cancer, Siegall is also transforming Seattle Genetics from a standard biotech R&D firm to a company that can also handle its own international marketing. Initially, international commercial rights had been sold to Takeda Oncology in order to raise money for research into Adcetris, but that partnership allowed Seattle Genetics to learn about the intricacies of global pharmaceutical marketing which led to it opening an office in Switzerland to begin its own international marketing and branding.
Seattle Genetics has grown tremendously in the recent past under Siegall’s leadership, with share prices more than tripling in the past 5 years and its sales of $418 million in 2016 representing a 46% spike from revenues in 2014. These metrics show the great potential of Siegall as the leader of the company.
The man behind arguably the biggest biotech company of the future, Clay Siegall, graduated with a bachelor’s degree in Zoology from the University of Maryland followed by a PhD in Genetics from George Washington University. Dr. Siegall previously worked at the National Cancer Institute under the National Institutes of Health from 1988 to 1991 before being employed by the Bristol-Myers Squibb Pharmaceutical Research Institute for the next 6 years. Dr. Siegall is a prolific researcher, with 70 publications and 15 patents to his name, and to top it off, he also serves as a board member at Alder BioPharmaceuticals, a private biotech company.